Insider · CIK 0001315018
Maria-Luisa Maccecchini
Files at ANVS (Annovis Bio, Inc.), LTRN (Lantern Pharma Inc.). First filing Nov 12, 2025, latest Nov 12, 2025.
In brief
Maria-Luisa Maccecchini files SEC Form 4 as CEO, president, director and 10% owner at ANVS (Annovis Bio, Inc.), and also at LTRN (Lantern Pharma Inc.). Since Nov 12, 2025, Maria-Luisa Maccecchini has reported 1 open-market buy worth $200k and 0 open-market sells worth $0, the latest filed on Nov 12, 2025.
A track record needs three past buys with six months of prices behind them; Maria-Luisa Maccecchini has 0, so none is measured yet.
The newest scored trade: bought $200k of ANVS on Oct 28, 2025, filed Nov 12, 2025, scored 48 (moderate). In the last 12 months: 1 buy worth $200k and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
ANVS: Annovis Bio, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 48Moderate | Annovis Bio, Inc. | $200k 97,561 shares | +9% | - |
Transactions
Every row this insider has filed, 11 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 9, 2026 | LTRN Lantern Pharma Inc. | AGrant or award Stock Option (Right to Buy)derivative | +25,000 | $0.00 | $0 | 25,000 | Jan 13, 2026 |
| Jan 9, 2026 | LTRN Lantern Pharma Inc. | AGrant or award Stock Option (Right to Buy)derivative | +21,152 | $0.00 | $0 | 21,152 | Jan 13, 2026 |
| Oct 28, 2025 | ANVS Annovis Bio, Inc. | POpen-market purchase Common Stock | +97,561 | $2.05 | $200k | 1,212,020 | Nov 12, 2025 |
| Jun 4, 2025 | ANVS Annovis Bio, Inc. | AGrant or award Common Stock | +46,000 | $3.37 | $155k | 1,114,459 | Jun 5, 2025 |
| Mar 28, 2024 | ANVS Annovis Bio, Inc. | GGift Common Stock | -10,000 | $0.00 | $0 | 1,088,459 | Jul 3, 2024 |
| Mar 31, 2024 | ANVS Annovis Bio, Inc. | GGift Common Stock | -10,000 | $0.00 | $0 | 1,078,459 | Jul 3, 2024 |
| Mar 31, 2024 | ANVS Annovis Bio, Inc. | GGift Common Stock | -10,000 | $0.00 | $0 | 1,068,459 | Jul 3, 2024 |
| Nov 17, 2023 | ANVS Annovis Bio, Inc. | AGrant or award Stock Option (right to buy)derivative | +252,000 | $0.00 | $0 | 252,000 | Jul 3, 2024 |
| Nov 17, 2023 | ANVS Annovis Bio, Inc. | AGrant or award Stock Option (right to buy)derivative | +108,800 | $0.00 | $0 | 108,800 | Jul 3, 2024 |
| Nov 20, 2023 | ANVS Annovis Bio, Inc. | AGrant or award Common Stock | +40,970 | $6.10 | $250k | 1,098,459 | Nov 22, 2023 |
| Nov 20, 2023 | ANVS Annovis Bio, Inc. | AGrant or award Common Stock | +41,186 | $6.07 | $250k | 1,098,675 | Nov 21, 2023 |
Questions about Maria-Luisa Maccecchini
Answered from the filings on this page, as of the latest one.
Is Maria-Luisa Maccecchini buying or selling?
In the last 12 months Maria-Luisa Maccecchini reported 1 open-market buy worth $200k and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $200k of ANVS on Oct 28, 2025. Grants, option exercises and tax withholding are not counted.
How did Maria-Luisa Maccecchini's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Maria-Luisa Maccecchini has 0.
Where does Maria-Luisa Maccecchini file Form 4?
Maria-Luisa Maccecchini has filed Form 4 at ANVS (Annovis Bio, Inc.) as President and CEO; LTRN (Lantern Pharma Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.